Cargando…
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric an...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331102/ https://www.ncbi.nlm.nih.gov/pubmed/34354386 http://dx.doi.org/10.2147/BLCTT.S267569 |